PEPG•benzinga•
PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls
Summary
PepGen halts its Phase 2 CONNECT2 trial for PGN-EDO51 in DMD to assess 10 mg/kg cohort data, while advancing FREEDOM-DM1 studies in myotonic dystrophy.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 4, 2025 by benzinga